Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Osteoporosis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Osteoporosis
    Long-Term Use of Alendronate Puts Some Patients at Risk for Fracture - (DGNews)
    TopAbstracts in Osteoporosis 06/24/2008 - (DGNews)
    Ultrasound Exam May Predict Risk for Fractures From Osteoporosis in Elderly Women - (DGNews)
    Canadian Study Supports Osteoporosis Screening Every 5 Years - (DGNews)
    No Link Between Ibandronate and Atrial Fibrillation in Postmenopausal Osteoporosis Patients: Presented at EULAR - (DGDispatch)

    News archive

     Recent webcasts/CME - Osteoporosis
  • Updates in the Diagnosis and Management of Osteoporosis: A Rheumatology Perspective
  • Glucocorticoid-Induced Osteoporosis: From the Bedside to the Bench and Back to the Bedside
    Guidelines for Pharmacists: Interpreting the Medical Evidence for Bisphosphonates in Postmenopausal Osteoporosis (Credit no longer available)

    Webcasts/CME archive

     Recent cases - Osteoporosis
      A Clay-Shoveler's Fracture with Renal Transplantation and Osteoporosis: A Case Report
      Stress Fracture of the Femoral Neck in a 24-Year-Old Female with Anorexia Nervosa Induced Osteoporosis
      Osteoporosis in Elderly Men
      Osteoporosis and Amenorrhea in a Young Patient with von Hippel-Lindau Disease
      Synovitis Induced by Alendronic Acid can Present as Acute Carpal Tunnel Syndrome

      Cases archive
        




      my personal edition > osteoporosis > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Risedronate (Actonel) Produces Significant and Rapid Decrease in Vertebral Fracture Risk in Postmenopausal Osteoporotic Women: Presented at ASBMR

      By Jill Stein
      Special to DG News

      SAN ANTONIO, TX -- September 23, 2002 -- A 5 mg daily dose of the bisphosphonate risedronate (Actonel) significantly decreases the risk of moderate and severe vertebral fractures in postmenopausal women with osteoporosis, investigators reported at the 24th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR).

      Prior to the present analysis, risedronate had been demonstrated to be effective in reducing morphometric vertebral fractures by 65 and 61 percent in the VERT- NA and VERT-MN clinical studies, respectively. In addition, risedronate had been shown to decrease the risk of clinical vertebral fractures as early as six months. The VERT-MN and VERT-MA are similarly designed multicenter, double-blind studies in which 1,994 postmenopausal women with osteoporosis were randomized to treatment with risedronate, 5 mg daily, or placebo; all patients received supplemental calcium along with vitamin D if baseline serum levels were low.

      In the present analysis, Dr. Dieter Felsenberg, with the Benjamin Franklin University Hospital in Berlin, Germany, and colleagues elsewhere, analyzed data from the two trials in order to determine the vertebral fracture risk reduction with risedronate treatment on moderate or severe fractures during the first year of therapy.

      During the first year, 46 (4.6 percent) of 992 placebo-treated patients sustained a new moderate or severe vertebral fracture versus only 14 of 1,002 (1.4 percent) patients in the risedronate group. In patients treated with the bisphosphonate, the risk reduction in moderate and severe vertebral fractures at one year was 70.7 percent.

      The reductions in vertebral fracture risk were sustained over three years.

      "The fundamental goal of treatment is to prevent fractures," co-investigator Dr. Harry Genant, professor of radiology, medicine, epidemiology, and orthopedic surgery at the University of California, San Francisco, said. "The new findings, coupled with earlier data documenting decreases in the risk of a first vertebral fracture and multiple vertebral fractures, suggest that risedronate decreases fracture risk across a range of osteoporotic severity."

      The study was funded by the Alliance for Better Bone Health, a partnership between Procter & Gamble Pharmaceuticals and Aventis.



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send